Moderna (MRNA) Deferred Taxes (2021 - 2023)

Moderna (MRNA) has 3 years of Deferred Taxes data on file, last reported at -$106.0 million in Q4 2023.

• Deferred Taxes for Q4 2023 came in at -$106.0 million, down 0.95% year-over-year; the trailing twelve-month figure through Sep 2024 was -$106.0 million (down 112.79% YoY), and the FY2023 annual result was $828.0 million, up 243.25% from the prior year.
• Deferred Taxes eased to -$106.0 million in Q4 2023 per MRNA's latest filing, from $1.5 billion in the prior quarter.
• Over five years, Deferred Taxes peaked at $1.5 billion in Q3 2023 and troughed at -$310.0 million in Q1 2023.
• A 3-year average of -$3.8 million and a median of -$105.5 million in 2022 frame the typical range for Deferred Taxes.
• The sharpest annual moves came in 2022 and 2023: Deferred Taxes tumbled 945.45% in 2022, then soared 1609.28% in 2023.
• A 3-year view of Deferred Taxes shows it stood at -$207.0 million in 2021, then jumped by 49.28% to -$105.0 million in 2022, then retreated by 0.95% to -$106.0 million in 2023.
• Business Quant data shows MRNA's Deferred Taxes at -$106.0 million in Q4 2023, $1.5 billion in Q3 2023, and -$220.0 million in Q2 2023.